Jump to content

Draft:Ling Qi: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Lqi1074 (talk | contribs)
9 edits
m i have added the links in some places and deleted links in others as suggested. Thank you for your time and suggestions.
Citation bot (talk | contribs)
Bots
5,689,724 edits
Alter: title, doi, template type. Add: bibcode, pmid, pages, issue, volume, doi, journal, pmc, doi-access, date, authors 1-24. Removed URL that duplicated identifier. Removed access-date with no URL. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by LeapTorchGear | Category:Pending_AfC_submissions | #UCB_Category 72/368
 
Line 28: Line 28:


<!-- EDIT BELOW THIS LINE -->
<!-- EDIT BELOW THIS LINE -->
'''Ling Qi''' (齐岭) is a Chinese-American biomedical scientist and academic specializing in [[endoplasmic-reticulum-associated protein degradation]] (ERAD) and its role in cellular homeostasis and disease. He is currently Chair of the Department of Molecular Physiology and Biological Physics at the [[University of Virginia]] School of Medicine, where he holds the Andrew P. Somlyo Distinguished Professorship in Molecular Physiology.<ref>{{Cite web|title=Ling Qi, PhD, to Chair UVA’s Department of Molecular Physiology and Biological Physics|url=https://news.med.virginia.edu/research/ling-qi-phd-to-chair-uvas-department-of-molecular-physiology-and-biological-physics-3/|website=UVA Health Newsroom}}</ref>
'''Ling Qi''' (齐岭) is a Chinese-American biomedical scientist and academic specializing in [[endoplasmic-reticulum-associated protein degradation]] (ERAD) and its role in cellular homeostasis and disease. He is currently Chair of the Department of Molecular Physiology and Biological Physics at the [[University of Virginia]] School of Medicine, where he holds the Andrew P. Somlyo Distinguished Professorship in Molecular Physiology.<ref>{{Cite web|title=Ling Qi, PhD, to Chair UVA's Department of Molecular Physiology and Biological Physics|url=https://news.med.virginia.edu/research/ling-qi-phd-to-chair-uvas-department-of-molecular-physiology-and-biological-physics-3/|website=UVA Health Newsroom|date=3 May 2023 }}</ref>


Qi’s research focuses on the intersection of protein quality control, metabolism, and disease, including [[diabetes mellitus|diabetes]], [[obesity]], and [[neurodevelopmental disorder|neurodevelopmental disorders]].
Qi’s research focuses on the intersection of protein quality control, metabolism, and disease, including [[diabetes mellitus|diabetes]], [[obesity]], and [[neurodevelopmental disorder|neurodevelopmental disorders]].
Line 38: Line 38:
Qi launched his independent research program in 2007 at [[Cornell University]]’s Division of Nutritional Sciences, where he was promoted to tenured Associate Professor in 2013. He moved to the [[University of Michigan Medical School]] in 2016 and was recruited in 2023 to the [[University of Virginia, School of Medicine]].
Qi launched his independent research program in 2007 at [[Cornell University]]’s Division of Nutritional Sciences, where he was promoted to tenured Associate Professor in 2013. He moved to the [[University of Michigan Medical School]] in 2016 and was recruited in 2023 to the [[University of Virginia, School of Medicine]].


His work has focused on the [[Endoplasmic-reticulum-associated protein degradation|ERAD]] pathway, particularly the SEL1L-HRD1 complex. His group demonstrated its essential role in maintaining [[endoplasmic reticulum]] (ER) function and organismal homeostasis.<ref>{{Cite journal |last1=Sun |first1=S |last2=Shi |first2=G |last3=Han |first3=X |title=Sel1L is indispensable for mammalian ERAD, ER homeostasis and survival |journal=Proceedings of the National Academy of Sciences |volume=111 |issue=5 |pages=E582–E591 |year=2014 |doi=10.1073/pnas.1318344111 |pmid=24453213}}</ref> His lab later showed that ERAD regulates mitochondrial dynamics in brown adipocytes using 3D imaging techniques.<ref>{{Cite journal |last=Zhou |first=Z |title=Endoplasmic reticulum-associated degradation regulates mitochondrial dynamics in brown adipocytes |journal=Science |volume=368 |issue=6486 |pages=54–60 |year=2020 |doi=10.1126/science.aax3878 |pmid=32193362}}</ref>
His work has focused on the [[Endoplasmic-reticulum-associated protein degradation|ERAD]] pathway, particularly the SEL1L-HRD1 complex. His group demonstrated its essential role in maintaining [[endoplasmic reticulum]] (ER) function and organismal homeostasis.<ref>{{Cite journal |last1=Sun |first1=S |last2=Shi |first2=G |last3=Han |first3=X |title=Sel1L is indispensable for mammalian ERAD, ER homeostasis and survival |journal=Proceedings of the National Academy of Sciences |volume=111 |issue=5 |pages=E582–E591 |year=2014 |doi=10.1073/pnas.1318114111 |doi-access=free |pmid=24453213|pmc=3918815 }}</ref> His lab later showed that ERAD regulates mitochondrial dynamics in brown adipocytes using 3D imaging techniques.<ref>{{Cite journal |last=Zhou |first=Z |title=Endoplasmic reticulum-associated degradation regulates mitochondrial dynamics in brown adipocytes |journal=Science |volume=368 |issue=6486 |pages=54–60 |year=2020 |doi=10.1126/science.aax3878 |pmid=32193362|pmc=7409365 }}</ref>


In 2023, Qi’s lab delineated the role of SEL1L-HRD1 ERAD in innate immunity by regulating STING signaling.<ref>{{Cite web |title=SEL1L–HRD1 endoplasmic reticulum-associated degradation controls STING-mediated innate immunity by limiting the size of the activable STING pool|url=https://www.nature.com/articles/s41556-023-01138-4 |website=Nature Cell Biology |access-date=2025-06-18}}</ref> The findings were highlighted in expert perspectives.<ref>{{Cite web |title=Innate immunity gets an ERAD boost |url=https://www.nature.com/articles/s41556-023-01142-8 |website=Nature Cell Biology |access-date=2025-06-18}}</ref><ref>{{Cite web |title=Perspective: Connecting ERAD with immune regulation |url=https://www.nature.com/articles/s41556-023-01139-3 |website=Nature Cell Biology |access-date=2025-06-18}}</ref>
In 2023, Qi’s lab delineated the role of SEL1L-HRD1 ERAD in innate immunity by regulating STING signaling.<ref>{{Cite journal |title=SEL1L–HRD1 endoplasmic reticulum-associated degradation controls STING-mediated innate immunity by limiting the size of the activable STING pool|journal=Nature Cell Biology |date=2023 |doi=10.1038/s41556-023-01138-4 |last1=Ji |first1=Yewei |last2=Luo |first2=Yuan |last3=Wu |first3=Yating |last4=Sun |first4=Yao |last5=Zhao |first5=Lianfeng |last6=Xue |first6=Zhen |last7=Sun |first7=Mengqi |last8=Wei |first8=Xiaoqiong |last9=He |first9=Zinan |last10=Wu |first10=Shuangcheng Alivia |last11=Lin |first11=Liangguang Leo |last12=Lu |first12=You |last13=Chang |first13=Lei |last14=Chen |first14=Fei |last15=Chen |first15=Siyu |last16=Qian |first16=Wei |last17=Xu |first17=Xiaoxi |last18=Chen |first18=Shengnuo |last19=Pan |first19=Dongli |last20=Zhou |first20=Zhangsen |last21=Xia |first21=Sheng |last22=Hu |first22=Chih-Chi Andrew |last23=Liang |first23=Tingbo |last24=Qi |first24=Ling |volume=25 |issue=5 |pages=726–739 |pmid=37142791 |pmc=10185471 }}</ref> The findings were highlighted in expert perspectives.<ref>{{Cite journal |title=Innate immunity gets an ERAD boost |url=https://www.nature.com/articles/s41556-023-01142-8 |journal=Nature Cell Biology |date=May 2023 |volume=25 |issue=5 |pages=635–636 |doi=10.1038/s41556-023-01142-8 |access-date=2025-06-18 |last1=Gao |first1=Kevin Mingjie |last2=Fitzgerald |first2=Katherine A. |pmid=37142792 }}</ref><ref>{{Cite journal |title=Perspective: Connecting ERAD with immune regulation |url=https://www.nature.com/articles/s41556-023-01139-3 |journal=Nature Cell Biology |date=May 2023 |volume=25 |issue=5 |pages=641–642 |doi=10.1038/s41556-023-01139-3 |pmid=37142790 |access-date=2025-06-18}}</ref>


His group has also identified genetic variants of SEL1L-HRD1 ERAD in human patients with neurodevelopmental disorders.<ref>{{Cite journal|last=Wang|first=HH|title=Hypomorphic variants of SEL1L-HRD1 ER-associated degradation are associated with neurodevelopmental disorders|journal=Journal of Clinical Investigation|volume=134|issue=2|pages=e170054|year=2024|doi=10.1172/JCI170054|pmid=37943610}}</ref> In the same year, his team published the structural resolution of the SEL1L-HRD1 core complex in mammalian cells.<ref>{{Cite web|title=Structure of the SEL1L-HRD1 complex|url=https://www.biorxiv.org/content/10.1101/2025.06.13.659592v1|website=bioRxiv}}</ref>
His group has also identified genetic variants of SEL1L-HRD1 ERAD in human patients with neurodevelopmental disorders.<ref>{{Cite journal|last=Wang|first=HH|title=Hypomorphic variants of SEL1L-HRD1 ER-associated degradation are associated with neurodevelopmental disorders|journal=Journal of Clinical Investigation|volume=134|issue=2|pages=e170054|year=2024|doi=10.1172/JCI170054|pmid=37943610|pmc=10786691 }}</ref> In the same year, his team published the structural resolution of the SEL1L-HRD1 core complex in mammalian cells.<ref>{{Cite journal|title=Structure of the SEL1L-HRD1 complex|url=https://www.biorxiv.org/content/10.1101/2025.06.13.659592v1|website=bioRxiv|date=2025 |doi=10.1101/2025.06.13.659592 |last1=Lin |first1=Liangguang Leo |last2=Maldosevic |first2=Emir |last3=Zhou |first3=Linyao Elina |last4=Jomaa |first4=Ahmad |last5=Qi |first5=Ling }}</ref>


As of 2025, Qi has authored over 100 peer-reviewed publications and 10 invited reviews. His work has been continuously funded by the [[National Institutes of Health]] and other organizations since 2007, with total support exceeding $25 million, including a recent grant from the [[National Institute on Aging]].<ref>{{Cite web |title=Ling Qi, PhD, Awarded $4.1 Million to Investigate Alzheimer’s Disease Pathogenesis |url=https://news.med.virginia.edu/research/ling-qi-phd-awarded-4-1-million-to-investigate-alzheimers-disease-pathogenesis/ |website=University of Virginia School of Medicine |date=March 26, 2024 |access-date=June 18, 2025}}</ref>
As of 2025, Qi has authored over 100 peer-reviewed publications and 10 invited reviews. His work has been continuously funded by the [[National Institutes of Health]] and other organizations since 2007, with total support exceeding $25 million, including a recent grant from the [[National Institute on Aging]].<ref>{{Cite web |title=Ling Qi, PhD, Awarded $4.1 Million to Investigate Alzheimer's Disease Pathogenesis |url=https://news.med.virginia.edu/research/ling-qi-phd-awarded-4-1-million-to-investigate-alzheimers-disease-pathogenesis/ |website=University of Virginia School of Medicine |date=March 26, 2024 |access-date=June 18, 2025}}</ref>


According to [[Google Scholar]], his h-index is 55.<ref>{{Cite web |title=Ling Qi – Google Scholar Citations |url=https://scholar.google.com/citations?user=tadr1D8AAAAJ&hl=en |website=Google Scholar |access-date=June 18, 2025}}</ref>
According to [[Google Scholar]], his h-index is 55.<ref>{{Cite web |title=Ling Qi – Google Scholar Citations |url=https://scholar.google.com/citations?user=tadr1D8AAAAJ&hl=en |website=Google Scholar |access-date=June 18, 2025}}</ref>


== Recognition and service ==
== Recognition and service ==
Qi was elected a Fellow of the [[American Association for the Advancement of Science]] (AAAS) in 2021 for "distinguished contributions to the fields of immunometabolism and cellular stress pathways."<ref>{{Cite journal|title=2021 AAAS Fellows approved by the AAAS Council|journal=Science|volume=375|issue=6577|year=2022|doi=10.1126/science.ada0325}}</ref> He has received awards from the [[American Diabetes Association]], American Federation for Aging Research, and American Society for Nutrition.
Qi was elected a Fellow of the [[American Association for the Advancement of Science]] (AAAS) in 2021 for "distinguished contributions to the fields of immunometabolism and cellular stress pathways."<ref>{{Cite journal|title=2021 AAAS Fellows approved by the AAAS Council|journal=Science|volume=375|issue=6577|year=2022|pages=393–397 |doi=10.1126/science.ada0325|bibcode=2022Sci...375..393. }}</ref> He has received awards from the [[American Diabetes Association]], American Federation for Aging Research, and American Society for Nutrition.


He has served as Chair of NIH study sections and as President of the Chinese American Diabetes Association. At the University of Michigan, he chaired the Biomedical Research Council.
He has served as Chair of NIH study sections and as President of the Chinese American Diabetes Association. At the University of Michigan, he chaired the Biomedical Research Council.


== Mentorship and teaching ==
== Mentorship and teaching ==
Qi has mentored over 100 trainees, including undergraduate and graduate students as well as postdoctoral fellows. He received the [[State University of New York|SUNY]] Chancellor’s Award for Excellence in Teaching in 2014<ref>{{Cite web|title=20 Cornellians win SUNY Chancellor’s Awards for Excellence|url=https://news.cornell.edu/stories/2014/05/20-cornellians-win-suny-chancellors-awards-excellence}}</ref> and twice served as faculty speaker at Cornell’s Nutritional Sciences graduation ceremonies.
Qi has mentored over 100 trainees, including undergraduate and graduate students as well as postdoctoral fellows. He received the [[State University of New York|SUNY]] Chancellor’s Award for Excellence in Teaching in 2014<ref>{{Cite web|title=20 Cornellians win SUNY Chancellor's Awards for Excellence|url=https://news.cornell.edu/stories/2014/05/20-cornellians-win-suny-chancellors-awards-excellence}}</ref> and twice served as faculty speaker at Cornell’s Nutritional Sciences graduation ceremonies.


== References ==
== References ==

Latest revision as of 17:25, 27 June 2025

  • Comment: In the links provided for the subject's association with Ostrand-Rosenberg, Carol Greider, and Marc Montminy, there is no mention of him. Please either delete these or provide other citations. Astra Travasso (talk) 18:44, 26 June 2025 (UTC)
  • Comment: Please add links. Only do this for the first use of a term that has an existing Wikipedia page. With these added the page is probably OK for acceptance. Ldm1954 (talk) 12:39, 22 June 2025 (UTC)
  • Comment: Well done on creating the draft, and it may potentially meet the relevant requirements (including WP:GNG, WP:ANYBIO, WP:NPROF) but presently it is not clear that it does.
    As other reviewers have noted, Wikipedia's basic requirement for entry is that the subject is notable. Essentially subjects are presumed notable if they have received significant coverage in multiple published secondary sources that are reliable, intellectually independent of each other, and independent of the subject. To properly create such a draft page, please see the articles ‘Your First Article’, ‘Referencing for Beginners’ and ‘Easier Referencing for Beginners’.
    Please note that many of the references are by the subject, rather than being about the subject.
    Please note that many of the references are not formatted correctly (see Introduction to referencing with VisualEditor and Wikipedia’s Manual of Style for help).
    Additionally, the draft tends to read too much like a promotional CV, which Wikipedia is not; and contains prose that is not of a standard appropriate for an encyclopaedia (also see WP:PEACOCK).
    Also, if you have any connection to the subject, including being the subject (see WP:AUTOBIO) or being paid, you have a conflict of interest that you must declare on your Talk page (to see instructions on how to do this please click the link).
    Please familiarise yourself with these pages before amending the draft. If you feel you can meet these requirements, then please make the necessary amendments before resubmitting the page. It would help our volunteer reviewers by identifying, on the draft's talk page, the WP:THREE best sources that establish notability of the subject.
    It would also be helpful if you could please identify with specificity, exactly which criteria you believe the page meets (eg "I think the page now meets WP:ANYBIO criteria #3, because XXXXX").
    Once you have implemented these suggestions, you may also wish to leave a note for me on my talk page and I would be happy to reassess. Cabrils (talk) 01:39, 18 June 2025 (UTC)

Ling Qi (齐岭) is a Chinese-American biomedical scientist and academic specializing in endoplasmic-reticulum-associated protein degradation (ERAD) and its role in cellular homeostasis and disease. He is currently Chair of the Department of Molecular Physiology and Biological Physics at the University of Virginia School of Medicine, where he holds the Andrew P. Somlyo Distinguished Professorship in Molecular Physiology.[1]

Qi’s research focuses on the intersection of protein quality control, metabolism, and disease, including diabetes, obesity, and neurodevelopmental disorders.

Early life and education

[edit]

Qi received his B.S. in Microbiology from Fudan University in Shanghai. He earned a Ph.D. in Immunology from the University of Maryland, Baltimore County in 2001, conducting research under immunologist Suzanne Ostrand-Rosenberg. He completed postdoctoral training in telomere biology and cancer with Carol Greider at Johns Hopkins University (2001–2004), followed by work on transcriptional regulation in metabolism with Marc Montminy, a member of the National Academy of Sciences.

Career and research

[edit]

Qi launched his independent research program in 2007 at Cornell University’s Division of Nutritional Sciences, where he was promoted to tenured Associate Professor in 2013. He moved to the University of Michigan Medical School in 2016 and was recruited in 2023 to the University of Virginia, School of Medicine.

His work has focused on the ERAD pathway, particularly the SEL1L-HRD1 complex. His group demonstrated its essential role in maintaining endoplasmic reticulum (ER) function and organismal homeostasis.[2] His lab later showed that ERAD regulates mitochondrial dynamics in brown adipocytes using 3D imaging techniques.[3]

In 2023, Qi’s lab delineated the role of SEL1L-HRD1 ERAD in innate immunity by regulating STING signaling.[4] The findings were highlighted in expert perspectives.[5][6]

His group has also identified genetic variants of SEL1L-HRD1 ERAD in human patients with neurodevelopmental disorders.[7] In the same year, his team published the structural resolution of the SEL1L-HRD1 core complex in mammalian cells.[8]

As of 2025, Qi has authored over 100 peer-reviewed publications and 10 invited reviews. His work has been continuously funded by the National Institutes of Health and other organizations since 2007, with total support exceeding $25 million, including a recent grant from the National Institute on Aging.[9]

According to Google Scholar, his h-index is 55.[10]

Recognition and service

[edit]

Qi was elected a Fellow of the American Association for the Advancement of Science (AAAS) in 2021 for "distinguished contributions to the fields of immunometabolism and cellular stress pathways."[11] He has received awards from the American Diabetes Association, American Federation for Aging Research, and American Society for Nutrition.

He has served as Chair of NIH study sections and as President of the Chinese American Diabetes Association. At the University of Michigan, he chaired the Biomedical Research Council.

Mentorship and teaching

[edit]

Qi has mentored over 100 trainees, including undergraduate and graduate students as well as postdoctoral fellows. He received the SUNY Chancellor’s Award for Excellence in Teaching in 2014[12] and twice served as faculty speaker at Cornell’s Nutritional Sciences graduation ceremonies.

References

[edit]
  1. ^ "Ling Qi, PhD, to Chair UVA's Department of Molecular Physiology and Biological Physics". UVA Health Newsroom. 3 May 2023.
  2. ^ Sun, S; Shi, G; Han, X (2014). "Sel1L is indispensable for mammalian ERAD, ER homeostasis and survival". Proceedings of the National Academy of Sciences. 111 (5): E582 – E591. doi:10.1073/pnas.1318114111. PMC 3918815. PMID 24453213.
  3. ^ Zhou, Z (2020). "Endoplasmic reticulum-associated degradation regulates mitochondrial dynamics in brown adipocytes". Science. 368 (6486): 54–60. doi:10.1126/science.aax3878. PMC 7409365. PMID 32193362.
  4. ^ Ji, Yewei; Luo, Yuan; Wu, Yating; Sun, Yao; Zhao, Lianfeng; Xue, Zhen; Sun, Mengqi; Wei, Xiaoqiong; He, Zinan; Wu, Shuangcheng Alivia; Lin, Liangguang Leo; Lu, You; Chang, Lei; Chen, Fei; Chen, Siyu; Qian, Wei; Xu, Xiaoxi; Chen, Shengnuo; Pan, Dongli; Zhou, Zhangsen; Xia, Sheng; Hu, Chih-Chi Andrew; Liang, Tingbo; Qi, Ling (2023). "SEL1L–HRD1 endoplasmic reticulum-associated degradation controls STING-mediated innate immunity by limiting the size of the activable STING pool". Nature Cell Biology. 25 (5): 726–739. doi:10.1038/s41556-023-01138-4. PMC 10185471. PMID 37142791.
  5. ^ Gao, Kevin Mingjie; Fitzgerald, Katherine A. (May 2023). "Innate immunity gets an ERAD boost". Nature Cell Biology. 25 (5): 635–636. doi:10.1038/s41556-023-01142-8. PMID 37142792. Retrieved 2025-06-18.
  6. ^ "Perspective: Connecting ERAD with immune regulation". Nature Cell Biology. 25 (5): 641–642. May 2023. doi:10.1038/s41556-023-01139-3. PMID 37142790. Retrieved 2025-06-18.
  7. ^ Wang, HH (2024). "Hypomorphic variants of SEL1L-HRD1 ER-associated degradation are associated with neurodevelopmental disorders". Journal of Clinical Investigation. 134 (2): e170054. doi:10.1172/JCI170054. PMC 10786691. PMID 37943610.
  8. ^ Lin, Liangguang Leo; Maldosevic, Emir; Zhou, Linyao Elina; Jomaa, Ahmad; Qi, Ling (2025). "Structure of the SEL1L-HRD1 complex". bioRxiv. doi:10.1101/2025.06.13.659592.
  9. ^ "Ling Qi, PhD, Awarded $4.1 Million to Investigate Alzheimer's Disease Pathogenesis". University of Virginia School of Medicine. March 26, 2024. Retrieved June 18, 2025.
  10. ^ "Ling Qi – Google Scholar Citations". Google Scholar. Retrieved June 18, 2025.
  11. ^ "2021 AAAS Fellows approved by the AAAS Council". Science. 375 (6577): 393–397. 2022. Bibcode:2022Sci...375..393.. doi:10.1126/science.ada0325.
  12. ^ "20 Cornellians win SUNY Chancellor's Awards for Excellence".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Ling_Qi&oldid=1297661630"